Molecular analysis of the cyclin-dependent kinase inhibitor family: p16(CDKN2/MTS1/INK4A), p18(INK4C) and p27(Kip1) genes in neuroblastomas

Cancer

Volumn 77, Issue 3, 1996, Pages 570-575

  Kawamata, Norihiko ^a,c   Seriu, Taku ^b   Koeffler, H Phillip ^a   Bartram, Claus R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CDKN2; cyclin dependent kinase inhibitor; INK4A; INK4C; Kip1; MTS1; p16; p18; p27; PCR SSCP; polymorphism

Indexed keywords

CYCLIN DEPENDENT KINASE; DNA; TRANSFERASE INHIBITOR;

ARTICLE; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; CHROMOSOME 1P; CLINICAL FEATURE; CONTROLLED STUDY; DNA SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MULTIGENE FAMILY; NEUROBLASTOMA; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; BLOTTING, SOUTHERN; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; GENE DELETION; GENES, TUMOR SUPPRESSOR; HUMANS; MOLECULAR SEQUENCE DATA; NEUROBLASTOMA; POINT MUTATION; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEINS;

EID: 0030051569     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960201)77:3<570::AID-CNCR21>3.0.CO;2-0     Document Type: Article

References (46)

1. Sherr CJ. Mammalian G1 cyclins. Cell 1993;73:1059-65.
2. Sherr CJ. G1 phase progression: cycling on cue. Cell 1994;79:551-6.
3. Hunter T. Braking the cycle. Cell 1993;75:839-41.
4. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994;371:257-61.
5. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/ CDK4. Nature 1993;366:704-7.
6. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson D. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753-6.
7. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
8. Prokocimer M, Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematological cell lineages. Blood 1994;84:2391-411.
9. Imamura J, Miyoshi I, Koeffler HP, p53 in hematologic malignancies. Blood 1994;84:2412-21.
10. Imamura J, Bartram CR, Berthold F, Harms D, Nakamura H, Koeffler HP. Mutation of the p53 gene in Neuroblastoma and its relationship with N-myc amplification. Cancer Res 1993;53:4053-8.
11. Castresana JS, Bello MJ, Rey JA, Nebreda P, Queizan A, Garcia-Miguel P, et al. No TP53 mutations in neuroblastomas detected by PCR-SSCP analysis. Genes Chromosom Cancer 1994;10:136-8.
12. Davidoff AM, Pence JC, Shorter NA, Iglehart JD, Marks JR. Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene 1992;7:127-33.
13. Hosoi G, Hara J, Okamura T, Osugi Y, Ishihara S, Fukuzawa M, et al. Low frequency of the p53 gene mutations in neuroblastoma. Cancer 1994;73:3087-93.
14. Komuro H, Hayashi Y, Kawamura M, Hayashi K, Kaneko Y, Kamoshita S, et al. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. Cancer Res 1993;53:5284-8.
15. Vogan K, Bernstein M, Leclerc JM, Brisson L, Brossard J, Brodeur GM, et al. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res 1993;53:5269-73.
16. Waber PG, Chen J, Nisen PD. Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas. Cancer Res 1993;53:6028-30.
17. El-Deiry W, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:815-25.
18. Gu Y, Turck CW, Morgan DO. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 1993;366:707-10.
19. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
20. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-4.
21. Jiang H, Fisher PB. Use of a sensitive and efficient substraction hybridization protocol for the identification of genes differentially regulated during the induction of differentiation in human melanoma cells. Mol Cell Differen 1993;1:285-99.
22. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994;211:90-8.
23. Shiohara M, El-Deiry WAS, Wada M, Nakamaki T, Takeuchi S, Yang R, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994;84:3781-4.
24. Fong CT, Dracopoli NC, White PS, Merrill PT, Griffith RC, Housman DE, et al. Loss of hererozygosity for the short arm of chromosome 1 in human neuroblastoma: correlation with N-myc amplification. Proc Natl Acad Sci USA 1989;86:3753-7.
25. Weith A, Martinsson T, Cziepluch C, Bruderlein S, Amler LC, Berthold F, et al. Neuroblastoma consensus deletion maps to 1p36.1-2. Genes Chromosom Cancer 1989;1:159-66.
26. Takeda O, Homma C, Maseki N, Sakurai M, Kanda N, Schwab M, et al. There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma. Genes Chromosom Cancer 1994;10:30-9.
27. Schleiermacher G, Peter M, Michon J, Hugot JP, Vielh P, Zucker JM, et al. Two distinct deleted regions on the short arm of chromosome I in neuroblastoma. Genes Chromosom Cancer 1994;10:275-81.
28. Kurahashi H, Oue T, Akagi K, Fukuzawa M, Okada A, Tawa A, et al. Allelic status on 1p and 11p15 in neuroblastoma and benign ganglioneuroma. Int J Oncol 1995;6:669-74.
29. INK4B/ MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994;8:2939-52.
30. kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78:59-66.
31. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 1994;78:67-74.
32. kip1, to regions involved in human cancer. Cancer Res 1995;55:1199-205.
33. kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 1995;55:1206-10.
34. Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1995;55:1211-4.
35. Brodeur GM, Seeger RC, Barrett A, Berhold F, Castleberry RP, D'Angio GJ, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988;6:1874-81.
36. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning, a Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
37. Hirama T, Miller CW, Wilczynski SP, Koeffler HP. Study of p16 (cyclin-dependent 4 kinase inhibitor/multiple tumor suppressor) gene in cancer of the uterine cervix. Modern Pathol. In press.
38. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene, p27/Kip1 in human malignancies. Cancer Res 1995;55:2266-9.
39. Hatta Y, Hirama T, Miller CW, Yamada Y, Tomonaga M, Koeffler HP. Homozygous deletions of the p15(MTS2) and p16(CDKN2/MTS1) genes in adult T-cell leukemia. Blood 1995;85:2699-704.
40. INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 1995;55:1448-51.
41. Spruck CHI, Gonzalez-Zulueta M, Shibata A, Gonzales F, Tsai IC, Jones PJ. p16 gene in uncultured tumors. Nature 1994;370:183-4.
42. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Tokino K, et al. Rates of p16(MTS1) mutations in primary tumors with 9p loss. Science 1994;265:415-6.
43. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Beymour AB, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27-32.
44. Hayashi N, Sugimoto Y, Tsuchiya E, Ogawa M, Nakamura Y. Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4I (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem Biophys Res Commun 1994;202:1426-1430.
45. Mori T, Miura K, Aoki T, Nishihara T, Mori S, Nakamura Y. Frequent somatic mutation of the CDKN2/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994;54:3396-3397.
46. Beltinger CP, White PS, Sulman EP, Maris JM, Brodeur GM. No CDKN2 mutations in neuroblastomas. Cancer Res 1995;55:2053-5.